Arbutus Biopharma (NASDAQ:ABUS) Receives Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research note published on Friday morning,Benzinga reports. Chardan Capital currently has a $5.00 target price on the biopharmaceutical company’s stock. Chardan Capital also issued estimates for Arbutus Biopharma’s FY2025 earnings at ($0.30) EPS.

A number of other equities analysts have also recently commented on ABUS. StockNews.com cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Arbutus Biopharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Arbutus Biopharma Trading Up 7.0 %

Shares of Arbutus Biopharma stock opened at $3.50 on Friday. The firm has a market cap of $663.22 million, a PE ratio of -8.14 and a beta of 1.93. The stock has a 50 day moving average of $3.34 and a 200 day moving average of $3.57. Arbutus Biopharma has a 12 month low of $2.30 and a 12 month high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings data on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The business had revenue of $1.57 million for the quarter, compared to analysts’ expectations of $2.20 million. As a group, equities research analysts forecast that Arbutus Biopharma will post -0.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arbutus Biopharma

Institutional investors have recently made changes to their positions in the company. Invesco Ltd. raised its position in Arbutus Biopharma by 5.7% in the 4th quarter. Invesco Ltd. now owns 69,831 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 3,780 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Arbutus Biopharma by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 40,179 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 3,870 shares during the period. Clear Harbor Asset Management LLC lifted its position in shares of Arbutus Biopharma by 6.7% during the fourth quarter. Clear Harbor Asset Management LLC now owns 79,761 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 5,000 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Arbutus Biopharma by 18.7% in the fourth quarter. Teacher Retirement System of Texas now owns 42,144 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 6,644 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Arbutus Biopharma by 10.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,397 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 8,308 shares in the last quarter. Institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.